Does the media refer more to AMRX or CMPS?

In the previous week, Compass Pathways had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Compass Pathways and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Compass Pathways' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INDV or CMPS more profitable?

Indivior has a net margin of 26.65% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 26.65% -283.11% 36.85% Compass Pathways N/A -49.63% -13.08%

Does the media prefer INDV or CMPS?

In the previous week, Indivior had 5 more articles in the media than Compass Pathways. MarketBeat recorded 20 mentions for Indivior and 15 mentions for Compass Pathways. Indivior's average media sentiment score of 0.87 beat Compass Pathways' score of 0.38 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CMPS or DFTX?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is CMPS or DFTX more profitable?

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Definium Therapeutics N/A -84.01% -63.66%

Does the media favor CMPS or DFTX?

In the previous week, Definium Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 17 mentions for Definium Therapeutics and 15 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.38 beat Definium Therapeutics' score of -0.07 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CMPS or MANE?

Veradermics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Veradermics N/A N/A -$70M -$1.32 N/A

Is CMPS or MANE more profitable?

Veradermics' return on equity of 0.00% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Veradermics N/A N/A N/A

Does the media prefer CMPS or MANE?

In the previous week, Compass Pathways had 12 more articles in the media than Veradermics. MarketBeat recorded 15 mentions for Compass Pathways and 3 mentions for Veradermics. Compass Pathways' average media sentiment score of 0.38 beat Veradermics' score of -0.21 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, EWTX or CMPS?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is EWTX or CMPS more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Compass Pathways N/A -49.63% -13.08%

Does the media refer more to EWTX or CMPS?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Compass Pathways. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 15 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.38 beat Edgewise Therapeutics' score of -0.24 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compass Pathways (CMPS) Competitors

$13.15 -0.39 (-2.88%)

As of 01:45 PM Eastern

Compare

CMPS vs. AMRX, INDV, DFTX, MANE, and EWTX

Should you buy Compass Pathways stock or one of its competitors? MarketBeat compares Compass Pathways with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Pathways include Amneal Pharmaceuticals (AMRX), Indivior (INDV), Definium Therapeutics (DFTX), Veradermics (MANE), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceuticals" industry.

How does Compass Pathways compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Amneal Pharmaceuticals currently has a consensus target price of $17.67, suggesting a potential downside of 1.96%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 77.96%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts clearly believe Compass Pathways is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Amneal Pharmaceuticals has a net margin of 5.05% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Compass Pathways	N/A	-49.63%	-13.08%

Amneal Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.90	$72.06M	$0.49	36.77
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

In the previous week, Compass Pathways had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Compass Pathways and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Compass Pathways' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals and Compass Pathways tied by winning 8 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Indivior?

Indivior (NASDAQ:INDV) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Indivior had 5 more articles in the media than Compass Pathways. MarketBeat recorded 20 mentions for Indivior and 15 mentions for Compass Pathways. Indivior's average media sentiment score of 0.87 beat Compass Pathways' score of 0.38 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.3% of Indivior shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Indivior has a net margin of 26.65% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Compass Pathways	N/A	-49.63%	-13.08%

Indivior presently has a consensus price target of $45.17, indicating a potential upside of 17.35%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 77.96%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Indivior has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.33B	3.41	$210M	$2.79	13.79
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Indivior has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

Summary

Indivior beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Definium Therapeutics?

Compass Pathways (NASDAQ:CMPS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Definium Therapeutics	N/A	-84.01%	-63.66%

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

In the previous week, Definium Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 17 mentions for Definium Therapeutics and 15 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.38 beat Definium Therapeutics' score of -0.07 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Compass Pathways presently has a consensus target price of $23.36, suggesting a potential upside of 77.96%. Definium Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 24.69%. Given Compass Pathways' higher possible upside, equities analysts plainly believe Compass Pathways is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Compass Pathways beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Veradermics?

Compass Pathways (NASDAQ:CMPS) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Veradermics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

Veradermics' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Veradermics	N/A	N/A	N/A

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Compass Pathways currently has a consensus price target of $23.36, indicating a potential upside of 77.96%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 40.24%. Given Compass Pathways' stronger consensus rating and higher probable upside, equities analysts plainly believe Compass Pathways is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Compass Pathways had 12 more articles in the media than Veradermics. MarketBeat recorded 15 mentions for Compass Pathways and 3 mentions for Veradermics. Compass Pathways' average media sentiment score of 0.38 beat Veradermics' score of -0.21 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Pathways beats Veradermics on 9 of the 13 factors compared between the two stocks.

How does Compass Pathways compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

46.2% of Compass Pathways shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Edgewise Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Edgewise Therapeutics' return on equity of -39.01% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Compass Pathways	N/A	-49.63%	-13.08%

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Compass Pathways. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 15 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.38 beat Edgewise Therapeutics' score of -0.24 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics currently has a consensus target price of $48.75, suggesting a potential upside of 12.33%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 77.96%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts clearly believe Compass Pathways is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Compass Pathways beats Edgewise Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.77B	$11.92B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-2.84	788.54	269.97	24.82
Price / Sales	N/A	967.38	650.66	108.09
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	-23.86	10.33	11.26	6.44
Net Income	-$287.86M	$2.77B	$3.45B	$347.27M
7 Day Performance	16.67%	1.99%	3.62%	2.55%
1 Month Performance	-3.78%	-1.56%	-0.56%	-1.02%
1 Year Performance	198.97%	191.17%	77.38%	23.33%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	2.9938 of 5 stars	$13.15 -2.9%	$23.36 +77.6%	+208.4%	$1.77B	N/A	N/A	120	Earnings Report Analyst Forecast
AMRX Amneal Pharmaceuticals	3.3964 of 5 stars	$18.85 +2.9%	$17.67 -6.3%	+112.4%	$5.84B	$3.02B	38.47	8,500
INDV Indivior	3.7509 of 5 stars	$37.37 -6.6%	$43.67 +16.8%	+76.5%	$4.88B	$1.24B	19.16	1,051	Earnings Report Analyst Upgrade High Trading Volume
DFTX Definium Therapeutics	3.4137 of 5 stars	$41.79 -4.0%	$54.85 +31.2%	+368.4%	$4.34B	N/A	N/A	40	Earnings Report Analyst Forecast
MANE Veradermics	2.2086 of 5 stars	$100.97 -3.8%	$153.00 +51.5%	N/A	$4.22B	N/A	N/A	19	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. AMRX, INDV, DFTX, MANE, and EWTX

How does Compass Pathways compare to Amneal Pharmaceuticals?

Summary

How does Compass Pathways compare to Indivior?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Summary

How does Compass Pathways compare to Veradermics?

Summary

How does Compass Pathways compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. AMRX, INDV, DFTX, MANE, and EWTX

How does Compass Pathways compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or CMPS?

Is AMRX or CMPS more profitable?

Which has higher earnings and valuation, AMRX or CMPS?

Does the media refer more to AMRX or CMPS?

Which has more risk & volatility, AMRX or CMPS?

Do institutionals & insiders hold more shares of AMRX or CMPS?

Summary

How does Compass Pathways compare to Indivior?

Does the media prefer INDV or CMPS?

Do institutionals and insiders believe in INDV or CMPS?

Is INDV or CMPS more profitable?

Do analysts prefer INDV or CMPS?

Which has preferable earnings and valuation, INDV or CMPS?

Which has more risk and volatility, INDV or CMPS?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Do insiders and institutionals have more ownership in CMPS or DFTX?

Is CMPS or DFTX more profitable?

Which has higher earnings & valuation, CMPS or DFTX?

Does the media favor CMPS or DFTX?

Which has more volatility and risk, CMPS or DFTX?

Do analysts prefer CMPS or DFTX?

Summary

How does Compass Pathways compare to Veradermics?

Which has higher valuation and earnings, CMPS or MANE?

Is CMPS or MANE more profitable?

Do insiders & institutionals have more ownership in CMPS or MANE?

Do analysts recommend CMPS or MANE?

Does the media prefer CMPS or MANE?

Summary

How does Compass Pathways compare to Edgewise Therapeutics?

Which has preferable earnings & valuation, EWTX or CMPS?

Do insiders & institutionals have more ownership in EWTX or CMPS?

Which has more volatility & risk, EWTX or CMPS?

Is EWTX or CMPS more profitable?

Does the media refer more to EWTX or CMPS?

Do analysts rate EWTX or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools